Recent studies have suggested that PARPi therapy may exert anti-PCa effects through activating MEG3 and thereby promoting PARP cleavage (Wang et al., 2018; Shan et al., 2020; Zou et al., 2019). The gene discussed is PARP1; the disease is posterior cortical atrophy.